Risk factors for mortality in patients with AIDS in the era of highly active antiretroviral therapy

被引:80
作者
Jabs, DA
Holbrook, JT
Van Natta, ML
Clark, R
Jacobson, MA
Kempen, JH
Murphy, RL
机构
[1] Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD USA
[2] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD USA
[3] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA
[4] Louisiana State Univ, Sch Med, Dept Med, New Orleans, LA USA
[5] Univ Calif San Francisco, Dept Med, San Francisco, CA USA
[6] Northwestern Univ, Feinberg Sch Med, Chicago, IL USA
关键词
D O I
10.1016/j.ophtha.2004.10.049
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Objective: To evaluate risk factors for mortality among patients with AIDS in the era of highly active antiretroviral therapy (HAART), particularly the effect of cytomegalovirus (CMV). Design: Prospective cohort study of patients with AIDS, conducted from 1998 through 2003. Participants: One thousand five hundred eighty-three patients with AIDS, of whom 374 had CMV retinitis. Methods: Patients were contacted every 3 months, with examinations at least every 6 months, in which standardized data were collected on AIDS history and treatment, eye examinations, and hematologic, virologic, and immunologic laboratory data. Main Outcome Measure: Mortality. Results: The overall mortality rate was 0.07 deaths/person -year. In a multivariate analysis, the following baseline risk factors were associated with an increased mortality: higher human immunodeficiency virus (HIV) viral load (relative risk [RR] = 4.6 for HIV viral load > 1 00 000 copies/ml vs. < 400 copies/ml; P < 0.0001), lower CD4+ T-cell count at enrollment (RR = 3.8 for CD4+ T cell count 0-49 cells/mu l vs.; >= 200 cells/bLI; P < 0.0001), CMV viral load >= 400 copies/ml (RR = 1.9; P = 0.002), lower hemoglobin (RR = 1.7 for hemoglobin < 10 g/dl; P = 0.009), a history of cryptococcal meningitis (RR = 1.7; P = 0.02), CMV retinitis (RR = 1.6; P = 0.0002), and Karnofsky score <= 80 (RR = 1.4; P = 0.008). Conclusions: In the era of HAART, CMV disease as manifested by CMV retinitis and a detectable CMV viral load were associated with an increased risk for mortality, even after adjusting for demographic, treatment, immunologic, and HIV virologic factors. (c) 2005 by the American Academy of Ophthalmology.
引用
收藏
页码:771 / 779
页数:9
相关论文
共 56 条
[1]  
[Anonymous], 1992, MMWR Recomm Rep, V41, P1
[2]   Improved outcome of cytomegalovirus retinitis in AIDS patients after introduction of protease inhibitors [J].
Casado, JL ;
Perez-Elías, MJ ;
Martí-Belda, P ;
Antela, A ;
Suarez, M ;
Ciancas, E ;
Frutos, B ;
Perez, MD ;
Guerrero, A .
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES AND HUMAN RETROVIROLOGY, 1998, 19 (02) :130-134
[3]  
COX DR, 1972, J R STAT SOC B, V34, P187
[4]   IMMEDIATE-EARLY GENE REGION OF HUMAN CYTOMEGALOVIRUS TRANS-ACTIVATES THE PROMOTER OF HUMAN-IMMUNODEFICIENCY-VIRUS [J].
DAVIS, MG ;
KENNEY, SC ;
KAMINE, J ;
PAGANO, JS ;
HUANG, ES .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1987, 84 (23) :8642-8646
[5]   Loss of cytomegalovirus (CMV) viraemia following highly active antiretroviral therapy in the absence of specific anti-CMV therapy [J].
Deayton, J ;
Mocroft, A ;
Wilson, P ;
Emery, VC ;
Johnson, MA ;
Griffiths, PD .
AIDS, 1999, 13 (10) :1203-1206
[6]   Effectiveness of potent antiretroviral therapies on the incidence of opportunistic infections before and after AIDS diagnosis [J].
Detels, R ;
Tarwater, P ;
Phair, JP ;
Margolick, J ;
Riddler, SA ;
Muñoz, A .
AIDS, 2001, 15 (03) :347-355
[7]   INCIDENCE AND NATURAL-HISTORY OF CYTOMEGALOVIRUS DISEASE IN PATIENTS WITH ADVANCED HUMAN-IMMUNODEFICIENCY-VIRUS DISEASE TREATED WITH ZIDOVUDINE [J].
GALLANT, JE ;
MOORE, RD ;
RICHMAN, DD ;
KERULY, J ;
CHAISSON, RE ;
BARTLETT, J ;
MCAVINUE, S ;
BRYSON, Y ;
COHEN, H ;
FISCHL, M ;
BOLIN, T ;
KESSLER, H ;
BURROUGH, Y ;
MILDVAN, D ;
FOX, A ;
RICHMAN, D ;
FREEMAN, B ;
SIMON, G ;
GRABOWY, KW ;
CHERNOFF, D ;
DUFF, P ;
THOMPSON, S ;
BARRETT, K ;
AWE, R ;
CHAPMAN, R ;
LEONARD, S ;
BAINES, L ;
TURNER, P ;
HAWKINS, M ;
MURRAY, H ;
BOWERS, J ;
LANE, C ;
TILSON, H ;
ANDREWS, E ;
SMILEY, L .
JOURNAL OF INFECTIOUS DISEASES, 1992, 166 (06) :1223-1227
[8]   Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy [J].
Grabar, S ;
Le Moing, V ;
Goujard, C ;
Leport, C ;
Kazatchkine, MD ;
Costagliola, D ;
Weiss, L .
ANNALS OF INTERNAL MEDICINE, 2000, 133 (06) :401-410
[9]   Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy [J].
Hogg, RS ;
Yip, B ;
Chan, KJ ;
Wood, E ;
Craib, KJP ;
O'Shaughnessy, MV ;
Montaner, JSG .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (20) :2568-2577
[10]   Occurrence of cytomegalovirus retinitis after human immunodeficiency virus immunosuppression [J].
Hoover, DR ;
Peng, Y ;
Saah, A ;
Semba, R ;
Detels, RR ;
Rinaldo, CR ;
Phair, JP .
ARCHIVES OF OPHTHALMOLOGY, 1996, 114 (07) :821-827